Elevance Health, Inc. (NYSE:ELV) Receives $399.63 Consensus PT from Analysts

Shares of Elevance Health, Inc. (NYSE:ELV) have received a consensus rating of “Moderate Buy” from the twenty-two brokerages that are presently covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $396.55.

Several analysts recently issued reports on the company. Weiss Ratings upgraded Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. Jefferies Financial Group reduced their target price on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a research report on Friday. Truist Financial lowered their price target on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday. Sanford C. Bernstein cut their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a report on Friday. Finally, Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th.

Elevance Health Price Performance

NYSE:ELV opened at $342.01 on Thursday. The company has a market cap of $76.01 billion, a P/E ratio of 13.62, a P/E/G ratio of 1.93 and a beta of 0.50. The firm’s fifty day moving average price is $351.94 and its two-hundred day moving average price is $329.16. Elevance Health has a one year low of $273.71 and a one year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts expect that Elevance Health will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is presently 27.23%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. PKS Advisory Services LLC acquired a new stake in Elevance Health during the fourth quarter worth about $206,000. QRG Capital Management Inc. increased its stake in Elevance Health by 11.7% in the fourth quarter. QRG Capital Management Inc. now owns 11,388 shares of the company’s stock valued at $3,992,000 after acquiring an additional 1,191 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC lifted its stake in Elevance Health by 12.0% during the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,963 shares of the company’s stock worth $688,000 after purchasing an additional 210 shares during the last quarter. Avidian Wealth Enterprises LLC acquired a new stake in shares of Elevance Health in the 4th quarter valued at $213,000. Finally, Balentine LLC bought a new position in shares of Elevance Health in the 4th quarter valued at $389,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.